نتائج البحث

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial.

• Authors : Daley-Yates P; Respiratory Clinical Development, GSK Research and Development, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, UK. .; Keppler B

Subjects: Androstadienes*/Androstadienes*/Androstadienes*/therapeutic use ; Asthma*/Asthma*/Asthma*/diagnosis ; Asthma*/Asthma*/Asthma*/drug therapy

• Source: Respiratory research [Respir Res] 2022 Sep 20; Vol. 23 (1), pp. 258. Date of Electronic Publication: 2022 Sep 20.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.

• Authors : Ismaila AS; Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA. .; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. .

• Source: Respiratory research [Respir Res] 2024 Apr 01; Vol. 25 (1), pp. 152. Date of Electronic Publication: 2024 Apr 01.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.

• Authors : Ismaila AS; Value Evidence and Outcomes, R&D Global Medical, GSK, 1250 South Collegeville Road, Collegeville, PA, USA. .; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. .

Subjects: Nebulizers and Vaporizers*; Humans ; Retrospective Studies

• Source: Respiratory research [Respir Res] 2023 Sep 25; Vol. 24 (1), pp. 229. Date of Electronic Publication: 2023 Sep 25.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

• Authors : Bjermer L; Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden.; van Boven JFM

Subjects: Models, Economic*; Cost-Benefit Analysis/Cost-Benefit Analysis/Cost-Benefit Analysis/*methods ; Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/*economics

• Source: Respiratory research [Respir Res] 2017 Dec 11; Vol. 18 (1), pp. 206. Date of Electronic Publication: 2017 Dec 11.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.

• Authors : Watz H; Pulmonary Research Institute at LungenClinic Grosshandorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Woehrendamm 80, 22927, Grosshansdorf, Germany. .; Hohlfeld JM

Subjects: Asthma/Asthma/Asthma/*diagnosis ; Asthma/Asthma/Asthma/*drug therapy ; Bronchodilator Agents/Bronchodilator Agents/Bronchodilator Agents/*administration & dosage

• Source: Respiratory research [Respir Res] 2020 Apr 15; Vol. 21 (1), pp. 87. Date of Electronic Publication: 2020 Apr 15.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.

• Authors : Wedzicha JA; Respiratory Division, National Heart and Lung Institute, Imperial College London, London, UK. .; Singh D

Subjects: Sex Characteristics*; Bronchodilator Agents/Bronchodilator Agents/Bronchodilator Agents/*administration & dosage ; Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/*administration & dosage

• Source: Respiratory research [Respir Res] 2019 Jan 08; Vol. 20 (1), pp. 4. Date of Electronic Publication: 2019 Jan 08.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

• Authors : Anzueto AR; University of Texas Health Science Center and South Texas Veterans Healthcare System, University of Texas, San Antonio, TX, USA. .; Kostikas K

Subjects: Disease Progression*; Bronchodilator Agents/Bronchodilator Agents/Bronchodilator Agents/*administration & dosage ; Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/*administration & dosage

• Source: Respiratory research [Respir Res] 2018 Jun 20; Vol. 19 (1), pp. 121. Date of Electronic Publication: 2018 Jun 20.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier.

• Authors : Heijink IH; Department of Pathology & Medical Biology, Experimental Pulmonology and Inflammation Research, University of Groningen, University Medical Center Groningen,, Hanzeplein 1, NL-9713 GZ, Groningen, The Netherlands. .; Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. .

Subjects: Bronchi/Bronchi/Bronchi/*immunology ; Budesonide/Budesonide/Budesonide/*administration & dosage ; Epithelial Cells/Epithelial Cells/Epithelial Cells/*immunology

• Source: Respiratory research [Respir Res] 2016 Jan 06; Vol. 17, pp. 2. Date of Electronic Publication: 2016 Jan 06.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

• Authors : Day NC; GlaxoSmithKline, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, UK. .; Kumar S

Subjects: Androstadienes/Androstadienes/Androstadienes/*administration & dosage ; Benzyl Alcohols/Benzyl Alcohols/Benzyl Alcohols/*administration & dosage ; Chlorobenzenes/Chlorobenzenes/Chlorobenzenes/*administration & dosage

• Source: Respiratory research [Respir Res] 2020 Jun 05; Vol. 21 (1), pp. 139. Date of Electronic Publication: 2020 Jun 05.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.

• Authors : Kern DM; HealthCore, Inc., 123 Justison St, Suite 200, Wilmington, DE, 19801-5134, USA. .; Davis J

Subjects: Administrative Claims, Healthcare*; Budesonide, Formoterol Fumarate Drug Combination/Budesonide, Formoterol Fumarate Drug Combination/Budesonide, Formoterol Fumarate Drug Combination/*administration & dosage ; Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/*administration & dosage

• Source: Respiratory research [Respir Res] 2015 Apr 23; Vol. 16, pp. 52. Date of Electronic Publication: 2015 Apr 23.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium:

تفاصيل العنوان